MICRON TECHNOLOGY INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MICRON TECHNOLOGY INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Aug 30, 2018 | $8.44B | Oct 15, 2018 |
| FY2018 | May 31, 2018 | $7.80B | Oct 15, 2018 |
| FY2018 | Mar 1, 2018 | $7.35B | Oct 15, 2018 |
| FY2018 | Nov 30, 2017 | $6.80B | Oct 15, 2018 |
| FY2018 | Aug 31, 2017 | $6.14B | Oct 15, 2018 |
| FY2018 | Jun 1, 2017 | $5.57B | Oct 15, 2018 |
| FY2018 | Mar 2, 2017 | $4.65B | Oct 15, 2018 |
| FY2018 | Dec 1, 2016 | $3.97B | Oct 15, 2018 |
| FY2018 | Sep 1, 2016 | $12.40B | Oct 15, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $37.38B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $25.11B | Oct 3, 2025 |
| FY2025 | Aug 31, 2023 | $15.54B | Oct 3, 2025 |
| FY2024 | Sep 1, 2022 | $30.76B | Oct 4, 2024 |
| FY2023 | Sep 2, 2021 | $27.71B | Oct 6, 2023 |
| FY2020 | Sep 3, 2020 | $6.06B | Oct 19, 2020 |
| FY2020 | May 28, 2020 | $5.44B | Oct 19, 2020 |
| FY2020 | Feb 27, 2020 | $4.80B | Oct 19, 2020 |
| FY2020 | Nov 28, 2019 | $5.14B | Oct 19, 2020 |
| FY2020 | Aug 29, 2019 | $4.87B | Oct 19, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Aug 31, 2017 | $6.14B | Oct 26, 2017 |
| FY2017 | Jun 1, 2017 | $5.57B | Oct 26, 2017 |
| FY2017 | Mar 2, 2017 | $4.65B | Oct 26, 2017 |
| FY2017 | Dec 1, 2016 | $3.97B | Oct 26, 2017 |
| FY2017 | Sep 1, 2016 | $3.22B | Oct 26, 2017 |
| FY2017 | Jun 2, 2016 | $2.90B | Oct 26, 2017 |
| FY2017 | Mar 3, 2016 | $2.93B | Oct 26, 2017 |
| FY2017 | Dec 3, 2015 | $3.35B | Oct 26, 2017 |
| FY2016 | Sep 3, 2015 | $3.60B | Oct 28, 2016 |
| FY2016 | Jun 4, 2015 | $3.85B | Oct 28, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $14.87B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $5.61B | Oct 3, 2025 |
| FY2025 | Aug 31, 2023 | ($1.42B) | Oct 3, 2025 |
| FY2024 | Sep 1, 2022 | $13.90B | Oct 4, 2024 |
| FY2023 | Sep 2, 2021 | $10.42B | Oct 6, 2023 |
| FY2020 | Sep 3, 2020 | $2.07B | Oct 19, 2020 |
| FY2020 | May 28, 2020 | $1.76B | Oct 19, 2020 |
| FY2020 | Feb 27, 2020 | $1.36B | Oct 19, 2020 |
| FY2020 | Nov 28, 2019 | $1.37B | Oct 19, 2020 |
| FY2020 | Aug 29, 2019 | $1.40B | Oct 19, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $8.54B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $778.00M | Oct 3, 2025 |
| FY2025 | Aug 31, 2023 | ($5.83B) | Oct 3, 2025 |
| FY2024 | Sep 1, 2022 | $8.69B | Oct 4, 2024 |
| FY2023 | Sep 2, 2021 | $5.86B | Oct 6, 2023 |
| FY2020 | Sep 3, 2020 | $988.00M | Oct 19, 2020 |
| FY2020 | May 28, 2020 | $803.00M | Oct 19, 2020 |
| FY2020 | Feb 27, 2020 | $405.00M | Oct 19, 2020 |
| FY2020 | Nov 28, 2019 | $491.00M | Oct 19, 2020 |
| FY2020 | Aug 29, 2019 | $561.00M | Oct 19, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $9.77B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $1.30B | Oct 3, 2025 |
| FY2025 | Aug 31, 2023 | ($5.75B) | Oct 3, 2025 |
| FY2024 | Sep 1, 2022 | $9.70B | Oct 4, 2024 |
| FY2023 | Sep 2, 2021 | $6.28B | Oct 6, 2023 |
| FY2020 | Sep 3, 2020 | $1.16B | Oct 19, 2020 |
| FY2020 | May 28, 2020 | $888.00M | Oct 19, 2020 |
| FY2020 | Feb 27, 2020 | $440.00M | Oct 19, 2020 |
| FY2020 | Nov 28, 2019 | $518.00M | Oct 19, 2020 |
| FY2020 | Aug 29, 2019 | $650.00M | Oct 19, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $3.80B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $3.43B | Oct 3, 2025 |
| FY2025 | Aug 31, 2023 | $3.11B | Oct 3, 2025 |
| FY2024 | Sep 1, 2022 | $3.12B | Oct 4, 2024 |
| FY2023 | Sep 2, 2021 | $2.66B | Oct 6, 2023 |
| FY2022 | Sep 3, 2020 | $2.60B | Oct 7, 2022 |
| FY2021 | Aug 29, 2019 | $2.44B | Oct 8, 2021 |
| FY2020 | Aug 30, 2018 | $2.14B | Oct 19, 2020 |
| FY2019 | Aug 31, 2017 | $1.82B | Oct 17, 2019 |
| FY2018 | Sep 1, 2016 | $1.62B | Oct 15, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $1.21B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $1.13B | Oct 3, 2025 |
| FY2025 | Aug 31, 2023 | $920.00M | Oct 3, 2025 |
| FY2024 | Sep 1, 2022 | $1.07B | Oct 4, 2024 |
| FY2023 | Sep 2, 2021 | $894.00M | Oct 6, 2023 |
| FY2022 | Sep 3, 2020 | $881.00M | Oct 7, 2022 |
| FY2021 | Aug 29, 2019 | $836.00M | Oct 8, 2021 |
| FY2020 | Aug 30, 2018 | $813.00M | Oct 19, 2020 |
| FY2019 | Aug 31, 2017 | $743.00M | Oct 17, 2019 |
| FY2018 | Sep 1, 2016 | $659.00M | Oct 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $17.53B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $8.51B | Oct 3, 2025 |
| FY2025 | Aug 31, 2023 | $1.56B | Oct 3, 2025 |
| FY2024 | Sep 1, 2022 | $15.18B | Oct 4, 2024 |
| FY2023 | Sep 2, 2021 | $12.47B | Oct 6, 2023 |
| FY2022 | Sep 3, 2020 | $8.31B | Oct 7, 2022 |
| FY2021 | Aug 29, 2019 | $13.19B | Oct 8, 2021 |
| FY2020 | Aug 30, 2018 | $17.40B | Oct 19, 2020 |
| FY2019 | Aug 31, 2017 | $8.15B | Oct 17, 2019 |
| FY2018 | Sep 1, 2016 | $3.17B | Oct 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $15.86B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $8.39B | Oct 3, 2025 |
| FY2025 | Aug 31, 2023 | $7.68B | Oct 3, 2025 |
| FY2024 | Sep 1, 2022 | $12.07B | Oct 4, 2024 |
| FY2023 | Sep 2, 2021 | $10.03B | Oct 6, 2023 |
| FY2022 | Sep 3, 2020 | $8.22B | Oct 7, 2022 |
| FY2021 | Aug 29, 2019 | $9.78B | Oct 8, 2021 |
| FY2020 | Aug 30, 2018 | $8.88B | Oct 19, 2020 |
| FY2019 | Aug 31, 2017 | $4.73B | Oct 17, 2019 |
| FY2018 | Sep 1, 2016 | $5.82B | Oct 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $82.80B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $69.42B | Oct 3, 2025 |
| FY2024 | Aug 31, 2023 | $64.25B | Oct 4, 2024 |
| FY2023 | Sep 1, 2022 | $66.28B | Oct 6, 2023 |
| FY2022 | Sep 2, 2021 | $58.85B | Oct 7, 2022 |
| FY2021 | Sep 3, 2020 | $53.68B | Oct 8, 2021 |
| FY2020 | Aug 29, 2019 | $48.89B | Oct 19, 2020 |
| FY2019 | Aug 30, 2018 | $43.38B | Oct 17, 2019 |
| FY2018 | Aug 31, 2017 | $35.34B | Oct 15, 2018 |
| FY2017 | Sep 1, 2016 | $27.54B | Oct 26, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $28.63B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $24.29B | Oct 3, 2025 |
| FY2024 | Aug 31, 2023 | $20.13B | Oct 4, 2024 |
| FY2023 | Sep 1, 2022 | $16.38B | Oct 6, 2023 |
| FY2022 | Sep 2, 2021 | $14.92B | Oct 7, 2022 |
| FY2021 | Sep 3, 2020 | $14.68B | Oct 8, 2021 |
| FY2020 | Aug 29, 2019 | $12.02B | Oct 19, 2020 |
| FY2019 | Aug 30, 2018 | $10.11B | Oct 17, 2019 |
| FY2018 | Aug 31, 2017 | $15.85B | Oct 15, 2018 |
| FY2017 | Sep 1, 2016 | $14.61B | Oct 26, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $54.17B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $45.13B | Oct 3, 2025 |
| FY2025 | Aug 31, 2023 | $44.12B | Oct 3, 2025 |
| FY2025 | Sep 1, 2022 | $49.91B | Oct 3, 2025 |
| FY2024 | Sep 2, 2021 | $43.93B | Oct 4, 2024 |
| FY2023 | Sep 3, 2020 | $39.00B | Oct 6, 2023 |
| FY2020 | Aug 29, 2019 | $35.88B | Oct 19, 2020 |
| FY2019 | Aug 30, 2018 | $32.29B | Oct 17, 2019 |
| FY2018 | Aug 31, 2017 | $18.62B | Oct 15, 2018 |
| FY2017 | Sep 1, 2016 | $12.08B | Oct 26, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $1.15B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $1.15B | Oct 3, 2025 |
| FY2024 | Aug 31, 2023 | $1.15B | Oct 4, 2024 |
| FY2023 | Sep 1, 2022 | $1.23B | Oct 6, 2023 |
| FY2022 | Sep 2, 2021 | $1.23B | Oct 7, 2022 |
| FY2021 | Sep 3, 2020 | $1.23B | Oct 8, 2021 |
| FY2020 | Aug 29, 2019 | $1.23B | Oct 19, 2020 |
| FY2019 | Aug 30, 2018 | $1.23B | Oct 17, 2019 |
| FY2018 | Aug 31, 2017 | $1.23B | Oct 15, 2018 |
| FY2017 | Sep 1, 2016 | $104.00M | Oct 26, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $48.58B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $40.88B | Oct 3, 2025 |
| FY2024 | Aug 31, 2023 | $40.82B | Oct 4, 2024 |
| FY2023 | Sep 1, 2022 | $47.27B | Oct 6, 2023 |
| FY2022 | Sep 2, 2021 | $39.05B | Oct 7, 2022 |
| FY2021 | Sep 3, 2020 | $33.38B | Oct 8, 2021 |
| FY2020 | Aug 29, 2019 | $30.76B | Oct 19, 2020 |
| FY2019 | Aug 31, 2018 | $24.49B | Oct 17, 2019 |
| FY2019 | Aug 30, 2018 | $24.40B | Oct 17, 2019 |
| FY2018 | Aug 31, 2017 | $10.26B | Oct 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $9.64B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $7.04B | Oct 3, 2025 |
| FY2024 | Aug 31, 2023 | $8.58B | Oct 4, 2024 |
| FY2023 | Sep 1, 2022 | $8.26B | Oct 6, 2023 |
| FY2022 | Sep 2, 2021 | $7.76B | Oct 7, 2022 |
| FY2021 | Sep 3, 2020 | $7.62B | Oct 8, 2021 |
| FY2020 | Aug 29, 2019 | $7.15B | Oct 19, 2020 |
| FY2019 | Aug 30, 2018 | $6.51B | Oct 17, 2019 |
| FY2018 | Aug 31, 2017 | $5.11B | Oct 15, 2018 |
| FY2017 | Sep 1, 2016 | $4.14B | Oct 26, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $11.53B | Oct 3, 2025 |
| FY2024 | Aug 29, 2024 | $11.34B | Oct 4, 2024 |
| FY2023 | Aug 31, 2023 | $12.05B | Oct 6, 2023 |
| FY2022 | Sep 1, 2022 | $6.02B | Oct 7, 2022 |
| FY2021 | Sep 2, 2021 | $5.97B | Oct 8, 2021 |
| FY2020 | Sep 3, 2020 | $6.16B | Oct 19, 2020 |
| FY2012 | Aug 30, 2012 | $3.26B | Oct 29, 2012 |
| FY2012 | Sep 1, 2011 | $2.00B | Oct 29, 2012 |
| FY2011 | Sep 2, 2010 | $2.36B | Oct 25, 2011 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | 7 | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | 0 | Oct 3, 2025 |
| FY2025 | Aug 31, 2023 | (5) | Oct 3, 2025 |
| FY2024 | Sep 1, 2022 | 7 | Oct 4, 2024 |
| FY2023 | Sep 2, 2021 | 5 | Oct 6, 2023 |
| FY2020 | Sep 3, 2020 | 0 | Oct 19, 2020 |
| FY2020 | May 28, 2020 | 0 | Oct 19, 2020 |
| FY2020 | Feb 27, 2020 | 0 | Oct 19, 2020 |
| FY2020 | Nov 28, 2019 | 0 | Oct 19, 2020 |
| FY2020 | Aug 29, 2019 | 0 | Oct 19, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | 7 | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | 0 | Oct 3, 2025 |
| FY2025 | Aug 31, 2023 | (5) | Oct 3, 2025 |
| FY2024 | Sep 1, 2022 | 7 | Oct 4, 2024 |
| FY2023 | Sep 2, 2021 | 5 | Oct 6, 2023 |
| FY2020 | Sep 3, 2020 | 0 | Oct 19, 2020 |
| FY2020 | May 28, 2020 | 0 | Oct 19, 2020 |
| FY2020 | Feb 27, 2020 | 0 | Oct 19, 2020 |
| FY2020 | Nov 28, 2019 | 0 | Oct 19, 2020 |
| FY2020 | Aug 29, 2019 | 0 | Oct 19, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | 1.12B | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | 1.11B | Oct 3, 2025 |
| FY2024 | Aug 31, 2023 | 1.10B | Oct 4, 2024 |
| FY2023 | Sep 1, 2022 | 1.09B | Oct 6, 2023 |
| FY2022 | Sep 2, 2021 | 1.12B | Oct 7, 2022 |
| FY2021 | Sep 3, 2020 | 1.11B | Oct 8, 2021 |
| FY2020 | Aug 29, 2019 | 1.11B | Oct 19, 2020 |
| FY2019 | Aug 30, 2018 | 1.16B | Oct 17, 2019 |
| FY2018 | Aug 31, 2017 | 1.11B | Oct 15, 2018 |
| FY2017 | Sep 1, 2016 | 1.04B | Oct 26, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 28, 2025 | $522.00M | Oct 3, 2025 |
| FY2025 | Aug 29, 2024 | $513.00M | Oct 3, 2025 |
| FY2023 | Aug 31, 2023 | $126.00M | Oct 6, 2023 |
| FY2023 | Jun 1, 2023 | $126.00M | Oct 6, 2023 |
| FY2023 | Mar 2, 2023 | $126.00M | Oct 6, 2023 |
| FY2023 | Dec 1, 2022 | $126.00M | Oct 6, 2023 |
| FY2024 | Sep 1, 2022 | $461.00M | Oct 4, 2024 |
| FY2023 | Sep 2, 2021 | $0 | Oct 6, 2023 |
| FY2022 | Sep 3, 2020 | $0 | Oct 7, 2022 |